We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I disagreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes’ innovative pipeline is led by our the BIOX-101 clinical-stage program for the prevention of thrombosis and neuroinflammation in intracerebral hemorrhage (ICH). We are also preparing BIOX-101 for a Phase 2 trial in ischemic stroke.
BIOX-101’s powerful dual mode of action inhibits the activation of neutrophils – the first responders of the immune system – and the release of the neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful anticoagulant effect. Crucially, it does so without increasing bleeding risk.
In parallel to its programs in stroke, Bioxodes is developing a pipeline of drug candidates to treat chronic thrombo-inflammatory and inflammatory diseases, leveraging BIOX-101’s inhibitory effect on the formation of the NETs.
BIOX-101 is our breakthrough lead candidate, designed to prevent secondary damage in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 is preparing for a potentially pivotal Phase 2b trial and has received Orphan Drug Designation in Europe and the U.S. for ICH. It is also on track for a Fast Track filing with the FDA and PRIME application in Europe.
In this short video, recorded with Bioxodes’ leadership, he highlights: BIOX-101 was safe in ICH patients, with no increase in hematoma volume—“the finding that struck me most.” Being able to administer BIOX-101 safely while helping prevent secondary thrombosis is “very, very important.” Edema data were promising; limiting edema expansion is a key driver of better outcomes. Watch the clip to learn more. The full webinar can be found on the investor page.
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
Leuven, Belgium
Edinburgh, United Kingdom
Berlin, Germany
Bern, Switzerland
Lille, France
Caen, France
Brussels, Belgium
Hamilton, Canada
Boston, United-States
Biotech Showcase JP Morgan week
January 12, 2026
San Francisco, United States
Bioxodes will be attending the JP Morgan week in San Francisco from 12 to 14 January 2026. Our CEO has been invited to join the panel discussion on shaping the future of brain health on January 14th. Reach out to us if you want to connect during the event!
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
December 10, 2025
Gosselies
Belgen jagen op ‘kerkhof voor investeerders’ op behandeling tegen hersenbloeding
December 10, 2025
Belgium
Het Waalse biotechbedrijf Bioxodes tankt 5,5 miljoen euro om zijn kandidaat-behandeling voor intracerebrale bloedingen na een beroerte te testen. ‘We willen nog eens 80 miljoen euro ophalen’, zegt CEO Marc Dechamps.
Bioxodes lève 5,5 millions pour financer la suite de ses recherches autour de l'AVC
December 10, 2025
Belgium
La biotech wallonne à la recherche d'un traitement pour les victimes d'AVC hémorragiques vient de lever 5,5 millions d'euros. De quoi financer sa prochaine étude clinique.
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
